Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

Autor: Vigon, L, Vazquez-Moron, S, Berenguer, J, Gonzalez-Garcia, J, Jimenez-Sousa, MA, Guardiola, JM, Crespo, M, de Los Santos, I, Von Wichmann, MA, Carrero, A, Yelamos, MB, Gomez, J, Resino, S, Martinez, I, Miralles, P, Lopez, JC, Parras, F, Padilla, B, Aldamiz-Echevarria, T, Tejerina, F, Diez, C, Perez-Latorre, L, Fanciulli, C, Gutierrez, I, Ramirez, M, Carretero, S, Bellon, JM, Bermejo, J, Hontanon, V, Arribas, JR, Montes, ML, Bernardino, I, Pascual, JF, Zamora, F, Pena, JM, Arnalich, F, Diaz, M, Domingo, P, Sanz, J, Bustinduy, MJ, Iribarren, JA, Rodriguez-Arrondo, F, Van den Eynde, E, Perez, M, Ribera, E, Casado, JL, Dronda, F, Morenoll, A, Perez-Elias, MJ, Sanfrutos, MA, Moreno, S, Quereda, C, Arranz, A, Casas, E, de Miguel, J, Schroeder, S, Vergas, J, Tellez, MJ, Vinuesa, D, Munoz, L, Hernandez-Quero, J, Ferrer, A, Galindo, MJ, Ortiz, L, Ortega, E, Montero, M, Blanes, M, Cuellar, S, Lacruz, J, Salavert, M, Lopez-Aldeguer, J, Perez, G, Gaspar, G, Yllescasl, M, Crespo, P, Aznar, E, Esteban, H
Rok vydání: 2019
Předmět:
Zdroj: Scientific Reports
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
SCIENTIFIC REPORTS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
ISSN: 2045-2322
Popis: The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFN alpha + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (552) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Databáze: OpenAIRE
Externí odkaz: